ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period from January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities during this period may be eligible for compensation. The lead plaintiff deadline is July 27, 2026.